Lansoprazolo Eg Stada

Lansoprazole, the active ingredient in Lansoprazolo Eg Stada, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is used to treat conditions such as gastro‑esophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection in adult patients.

GNH USA supplies Lansoprazolo Eg Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders. - Gastro‑esophageal reflux disease (GERD): reduces acid exposure and promotes healing of the esophageal lining. - Peptic ulcer disease: facilitates ulcer healing by decreasing gastric acidity. - Helicobacter pylori eradication: used in combination therapy to improve bacterial eradication rates. - Erosive esophagitis: aids mucosal recovery by limiting acid‑induced injury.

Lansoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may improve with continued therapy. - Nausea: feeling of unease or urge to vomit. - Abdominal pain: discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: infrequent or difficult bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: severe diarrhea due to bacterial overgrowth. - Liver enzyme elevation: increased ALT or AST levels indicating hepatic stress. - Low magnesium levels: may cause muscle cramps or irregular heartbeat. - Stevens‑Johnson syndrome: rare skin blistering condition. - Interstitial nephritis: inflammation of kidney tissue.

Before initiating therapy, consider the following precautions. - Renal function assessment: adjust use in patients with severe kidney impairment. - Infection monitoring: be alert for signs of gastrointestinal infections. - Elderly patients: start with the lowest effective dose and monitor response. - Concomitant NSAID use: increase risk of gastrointestinal bleeding; consider protective strategies. - Drug interaction review: evaluate all concurrent medications for potential interactions. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lansoprazole can affect the absorption and metabolism of several drugs.

Major Interactions (Avoid): - Ketoconazole: reduced absorption due to increased gastric pH. - Atazanavir: decreased plasma concentrations, compromising antiviral efficacy. - Itraconazole: impaired absorption leading to therapeutic failure. - Clarithromycin: increased risk of cardiac arrhythmias. - Clopidogrel: reduced activation, potentially diminishing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, requiring dose adjustment. - Methotrexate: elevated concentrations, especially at high doses. - Warfarin: enhanced anticoagulant effect, monitor INR. - Phenytoin: decreased levels, may reduce seizure control. - Calcium carbonate: may affect absorption of both agents.